PI3Kγ maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway
Blood · 2024
DOI: 10.1182/blood.2023022202 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, 2024. Verfasst von Hao Gu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Class Ib Phosphatidylinositol 3-Kinase, Leukemia, Myeloid, Acute, Neoplastic Stem Cells, Pentose Phosphate Pathway. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Acute myeloid leukemia (AML) is an aggressive hematological malignancy originating from transformed hematopoietic stem or progenitor cells. AML prognosis remains poor owing to resistance and relapse driven by leukemia stem cells (LSCs). Targeting molecules essential for LSC function is a promising therapeutic approach. The phosphatidylinositol 3-kinase (PI3K)/AKT pathway is often dysregulated in AML. We found that although PI3Kγ is highly enriched in LSCs and critical for self-renewal, it was dispensable for normal hematopoietic stem cells. Mechanistically, PI3Kγ-AKT signaling promotes nuclear factor erythroid 2-related factor 2 (NRF2) nuclear accumulation, which induces 6-phosphogluconate dehydrogenase (PGD) and the pentose phosphate pathway, thereby maintaining LSC stemness. Importantly, genetic or pharmacological inhibition of PI3Kγ impaired expansion and stemness of murine and human AML cells in vitro and in vivo. Together, our findings reveal a key role for PI3Kγ in selectively maintaining LSC function by regulating AKT-NRF2-PGD metabolic pathway. Targeting the PI3Kγ pathway may, therefore, eliminate LSCs without damaging normal hematopoiesis, providing a promising therapeutic strategy for AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA.
- Hongqiao International Institute of Medicine, Shanghai Tongren Hospital, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Faculty of Basic Medicine, Shanghai Jiao Tong University Sc…
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA.
- Moores Cancer Center, University of California, San Diego, La Jolla, CA.
- Department of Pathology and Medicine, University of California, San Diego, La Jolla, CA.
ORCID-Profile: Hao Gu, Ce Yang, Jean J Zhao
Förderung
- NCI NIH HHS
Zitieren
APA
Gu, H., Chen, C., Hou, Z. S., He, X. D., Xie, S., Ni, J., Qian, C., Cheng, X., Jiang, T., Yang, C., Roberts, T. M., Zheng, J., Varner, J. A., Armstrong, S. A., & Zhao, J. J. (2024). PI3Kγ maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway. Blood. https://doi.org/10.1182/blood.2023022202
Vancouver
Gu H, Chen C, Hou ZS, He XD, Xie S, Ni J, et al. PI3Kγ maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway. Blood. 2024. doi:10.1182/blood.2023022202
BibTeX
@article{Gu2024,
author = {Gu, Hao and Chen, Chiqi and Hou, Zhi-Shuai and He, Xia-Di and Xie, Shaozhen and Ni, Jing and Qian, Changli and Cheng, Xin and Jiang, Tao and Yang, Ce and Roberts, Thomas M and Zheng, Junke and Varner, Judith A and Armstrong, Scott A and Zhao, Jean J},
title = {PI3Kγ maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway},
journal = {Blood},
year = {2024},
doi = {10.1182/blood.2023022202}
}
EUVIMED